BOSTON and BELLEVUE, WA, June 20, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a leading nuclear innovation company, today announced they entered […] The post Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics first appeared on Ratio Therapeutics .